Windtree Therapeutics Inc (WINT) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.00 (+0.00%), Market cap $0.00B, P/E ratio 0.00, 52-week low–high $0.01 ~ $1.19.
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. Its lead product candidate is istaroxime, which is in Phase 2b clinical trials for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. The company also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trials to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant for the treatment of respiratory disease, disorder, or condition in humans; Rostafuroxin, which is in Phase 2b clinical trials for the treatment of genetical
Financial statements, price targets, institutional (13F) holdings and related news for Windtree Therapeutics Inc are updated in real time on BlackAll Trade.
Windtree Therapeutics Inc trades at $0.00 (+0.00%). Real-time quotes and charts are available on BlackAll Trade.
Windtree Therapeutics Inc has a market cap of about $0.00B. Its P/E ratio is 0.00.
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. Its lead product candidate is istaroxime, which is